Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARQT Arcutis Biotherapeutics Inc.

Trading 04-23 09:44:00 EDT

14.27

+0.44

+3.18%

High14.68	Low14.20	Vol139.01K
Open14.35	D1 Closing13.83	Amplitude3.47%
Mkt Cap1.69B	Tradable Cap1.22B	Total Shares118.64M
T/O2.00M	T/O Rate0.16%	Tradable Shares85.24M
P/B10.75	ROE-113.76%	EPS-1.16
52wk High17.75	52wk Low6.99	P/E-12.33
Dividend0.00	Div.Yield0.00	ROA-23.25%

暂无数据

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ARQT","market":"US","secType":"STK","nameCN":"Arcutis Biotherapeutics Inc.","latestPrice":14.27,"timestamp":1745415837273,"preClose":13.83,"halted":0,"volume":139009,"delay":0,"floatShares":85242342,"shares":118638235,"eps":-1.157752,"marketStatus":"Trading","change":0.44,"latestTime":"04-23 09:44:00 EDT","open":14.35,"high":14.68,"low":14.2,"amount":2002800.1778135,"amplitude":0.034707,"askPrice":14.37,"askSize":400,"bidPrice":14.28,"bidSize":70,"shortable":3,"etf":0,"ttmEps":-1.157752,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"listingDate":1580446800000,"exchange":"NASDAQ","adjPreClose":13.83,"preHourTrading":{"tag":"盘前","latestPrice":14.5,"preClose":13.83,"latestTime":"09:27 EDT","volume":4841,"amount":68725.11611100001,"timestamp":1745414870012},"postHourTrading":{"tag":"盘后","latestPrice":14.01,"preClose":13.83,"latestTime":"19:46 EDT","volume":836201,"amount":11565878.5016,"timestamp":1745365618411},"volumeRatio":1.724483,"impliedVol":0.8502,"impliedVolPercentile":0.496},"requestUrl":"/m/hq/s/ARQT/wiki","defaultTab":"wiki","newsList":[{"id":"2529350309","title":"Arcutis Biotherapeutics: Buy Rating Affirmed Amid Positive Long-Term Outlook and Strategic Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2529350309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529350309?lang=en_us&edition=full_marsco","pubTime":"2025-04-23 18:45","pubTimestamp":1745405147,"startTime":"0","endTime":"0","summary":"Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arcutis-biotherapeutics-buy-rating-affirmed-amid-positive-long-term-outlook-and-strategic-growth-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arcutis-biotherapeutics-buy-rating-affirmed-amid-positive-long-term-outlook-and-strategic-growth-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2528714676","title":"Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528714676","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528714676?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:00","pubTimestamp":1744891200,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., April 17, 2025  -- Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.A live webcast of the call and the presentation materials will be available on the “Events” section of The Company’s website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcutis-report-first-quarter-2025-120000769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ARQT","BK4588","BK4218","BK4181","BK4585","HST"],"gpt_icon":0},{"id":"2526547092","title":"Arcutis Biotherapeutics Promotes Vairavan to CFO as Topper Plans Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2526547092","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526547092?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 05:41","pubTimestamp":1744321260,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics promoted Latha Vairavan to chief financial officer, effective immediately, prior to the filing of the company's upcoming first-quarter financial report.Vairavan most recently was the company's vice president of finance and corporate controller, overseeing daily accounting operations and ensuring compliance with financial, accounting and income tax regulations, the company said Thursday.She joined the company in March 2020, having previously held roles of increasing responsibility at biopharmaceutical company Amgen.As CFO of Arcutis, Vairavan's annual base salary will increase to $450,000, according to a filing with the Securities and Exchange Commission. She will additionally be eligible for an annual bonus up to 67.5% of her annual salary, as well as stock options and other benefits.Vairavan will succeed David Topper, who plans to retire. Topper will provide transition support through his departure from the company, scheduled for May 15.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2526423435","title":"Arcutis Biotherapeutics Names New Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526423435","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526423435?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 05:03","pubTimestamp":1744318999,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics  said Thursday that Latha Vairavan, currently vice president and controller, will assume the role of chief financial officer.Vairavan will succeed David Topper, who is retiring from the firm, Arcutis said. Topper will continue as CFO until the company's Q1 filing and provide transition support through May 15.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2526054473","title":"Arcutis Biotherapeutics CFO David Topper to retire, Latha Vairavan to succeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2526054473","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526054473?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 04:40","pubTimestamp":1744317612,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics (ARQT) announced that David Topper, Arcutis’ CFO is retiring from the company and Latha Vairavan, currently vice president ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcutis-biotherapeutics-cfo-david-topper-to-retire-latha-vairavan-to-succeed?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcutis-biotherapeutics-cfo-david-topper-to-retire-latha-vairavan-to-succeed?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2526541613","title":"BRIEF-Arcutis Announces Chief Financial Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2526541613","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526541613?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 04:36","pubTimestamp":1744317402,"startTime":"0","endTime":"0","summary":"BRIEF-Arcutis Announces Chief Financial Officer TransitionArcutis Biotherapeutics Inc ARQT.O:ARCUTIS ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITIONARCUTIS BIOTHERAPEUTICS INC - CFO DAVID TOPPER TO RETIR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUAC3M2PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2526541361","title":"Arcutis Announces Chief Financial Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2526541361","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526541361?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 04:30","pubTimestamp":1744317001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUAC3M2PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2526365541","title":"Arcutis Biotherapeutics Inc - CFO David Topper to Retire","url":"https://stock-news.laohu8.com/highlight/detail?id=2526365541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526365541?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 04:30","pubTimestamp":1744317001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUAC3M2PJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2526541805","title":"Press Release: Arcutis Announces Chief Financial Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2526541805","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526541805?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 04:30","pubTimestamp":1744317000,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., April 10, 2025  -- Arcutis Biotherapeutics, Inc. , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, Arcutis' chief financial officer  is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Mr. Topper will continue to serve as CFO until the filing of the Company's first quarter 10-Q and will provide transition support through his departure on May 15, 2025.Mr. Topper, who has served as the Company's CFO since April 2024, has been instrumental in strengthening Arcutis' financial position, which has enabled the Company to continue investing in its future growth. Most notably, he renegotiated the Company's existing debt facility with SLR Investment Corp., revamped the Company's overall investor relations strategy, and led the Company's transition","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","BK4139","CFO","ARQT","BK4022"],"gpt_icon":0},{"id":"2526363921","title":"Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2526363921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526363921?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:09","pubTimestamp":1744200540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARQT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 08:09 ET (12:09 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT"],"gpt_icon":0},{"id":"2525737705","title":"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525737705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525737705?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:00","pubTimestamp":1743796800,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., April 04, 2025  -- Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,000 restricted stock units of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of April 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcutis-biotherapeutics-reports-inducement-grants-200000365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","NDAQ","BK4139","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4585","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP",".IXIC","ARQT","LU2210150020.SGD"],"gpt_icon":0},{"id":"2524058234","title":"Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2524058234","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524058234?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 18:31","pubTimestamp":1743676260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARQT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 06:31 ET (10:31 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT"],"gpt_icon":0},{"id":"2524349672","title":"Strategic Advantage and Market Confidence: Arcutis Biotherapeutics’ Extended Exclusivity and Buy Rating Amidst Competitive Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2524349672","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524349672?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 18:16","pubTimestamp":1743675411,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report), with a p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-advantage-and-market-confidence-arcutis-biotherapeutics-extended-exclusivity-and-buy-rating-amidst-competitive-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-advantage-and-market-confidence-arcutis-biotherapeutics-extended-exclusivity-and-buy-rating-amidst-competitive-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2524870812","title":"Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524870812","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524870812?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 16:47","pubTimestamp":1743670033,"startTime":"0","endTime":"0","summary":"We recently published a list of The Top 10 Performing Stocks on Wednesday. In this article, we are going to take a look at where Arcutis Biotherapeutics Inc.  stands against other top performing stocks on Wednesday.Wall Street’s three major indices finished in the green territory on Wednesday as investors continued to digest news of President Donald Trump’s tariff rollout on imports.The tech-heavy Nasdaq finished the day strongest, adding 0.87 percent. The S&P 500 grew 0.67 percent, while the Dow Jones was up 0.56 percent.Ten individual stocks mirrored a broader market optimism, closing the day in the green amid a series of corporate developments that sparked buying appetite.In this article, we named Wednesday’s top performers and detailed the reasons behind their gains.As part of the joint stipulation agreement, ARQT said that Padagis is required to report to ARQT any US Food and Drug Administration  correspondence regarding their Abbreviated New Drug Application  for their potential ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-arcutis-biotherapeutics-inc-arqt-084713101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","MNQmain","ARQT","QLD","PSQ","TQQQ","TSYW.SI",".IXIC","USJW.SI","BK4139","NVIW.SI","NQmain","QID","USAW.SI"],"gpt_icon":1},{"id":"2524242169","title":"Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2524242169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524242169?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 08:35","pubTimestamp":1743640556,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report), with a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/arcutis-biotherapeutics-arqt-receives-a-buy-from-mizuho-securities-7?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/arcutis-biotherapeutics-arqt-receives-a-buy-from-mizuho-securities-7?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARQT","BK4207","MFG"],"gpt_icon":0},{"id":"2524482774","title":"BRIEF-Arcutis And Padagis Agree To Stay Patent Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2524482774","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524482774?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 03:29","pubTimestamp":1743622199,"startTime":"0","endTime":"0","summary":"BRIEF-Arcutis And Padagis Agree To Stay Patent LawsuitApril 2 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O:ARCUTIS AND PADAGIS AGREE TO STAY PATENT LAWSUITARCUTIS BIOTHERAPEUTICS: PADAGIS TO REPORT ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2524124674","title":"BUZZ-Arcutis rises after halting patent dispute with Padagis","url":"https://stock-news.laohu8.com/highlight/detail?id=2524124674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524124674?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 01:58","pubTimestamp":1743616726,"startTime":"0","endTime":"0","summary":"BUZZ-Arcutis rises after halting patent dispute with Padagis**Shares of drugmaker Arcutis Biotherapeutics ARQT.O rise 12.9% to $16.91 ** Co says it has agreed to temporarily pause a patent lawsuit with Israel-based Padagis regarding the latter attempting to produce a generic version of ARQT's Zoryve** Zoryve is used to treat skin disorders including plaque psoriasis, seborrheic dermatitis and atopic dermatitis** As part of the agreement, Padagis will keep Arcutis updated on any communication with the FDA about their generic version of Zoryve. ** The patent for Zoryve is protected until at least 2037. ** Including session's moves, ARQT stock up 19.4% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nL6N3QG0QI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2524129714","title":"Arcutis Agrees to Stay Patent Lawsuit Against Padagis","url":"https://stock-news.laohu8.com/highlight/detail?id=2524129714","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524129714?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 01:48","pubTimestamp":1743616129,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics  said Wednesday it has acceded to a request by Padagis to stay a patent lawsuit over Arcutis' Zoryve cream 0.3% for plaque psoriasis.As part of a joint stipulation agreement filed in court Wednesday, Arcutis said Padagis is required to report to Arcutis any correspondence from the US Food and Drug Administration regarding its abbreviated new drug application for a potential generic alternative to Zoryve.The companies also agreed to extend the 30-month Hatch-Waxman stay of regulatory approval by one day for every day the litigation is stayed as of March 24, according to Arcutis.Patent protection for Zoryve cream 0.3% extends until 2037, Arcutis said.Shares of Arcutis were up more than 10% in recent trading.Price: 16.54, Change: +1.56, Percent Change: +10.41","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2524411007","title":"Arcutis Biotherapeutics: Padagis to Report to Co Any FDA Correspondence About Anda for Their Generic Alternative to Zoryve Cream 0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524411007","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524411007?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 01:16","pubTimestamp":1743614212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0FQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2524041171","title":"Arcutis and Padagis Agree to Stay Patent Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2524041171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524041171?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 01:16","pubTimestamp":1743614212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARQT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcutis.com","stockEarnings":[{"period":"1week","weight":0.0485},{"period":"1month","weight":-0.1869},{"period":"3month","weight":0.0088},{"period":"6month","weight":0.6445},{"period":"1year","weight":0.547},{"period":"ytd","weight":-0.0072}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.117216},{"month":2,"riseRate":0.833333,"avgChangeRate":0.23515},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027279},{"month":4,"riseRate":0.5,"avgChangeRate":0.03093},{"month":5,"riseRate":0.6,"avgChangeRate":-0.10059},{"month":6,"riseRate":0.8,"avgChangeRate":0.067805},{"month":7,"riseRate":0.6,"avgChangeRate":0.020773},{"month":8,"riseRate":0.4,"avgChangeRate":-0.035909},{"month":9,"riseRate":0.4,"avgChangeRate":-0.103428},{"month":10,"riseRate":0,"avgChangeRate":-0.25256},{"month":11,"riseRate":0.4,"avgChangeRate":0.133149},{"month":12,"riseRate":0.8,"avgChangeRate":0.194311}],"exchange":"NASDAQ","name":"Arcutis Biotherapeutics Inc.","nameEN":"Arcutis Biotherapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcutis Biotherapeutics Inc.,ARQT,Arcutis Biotherapeutics Inc.股票,Arcutis Biotherapeutics Inc.股票老虎,Arcutis Biotherapeutics Inc.股票老虎国际,Arcutis Biotherapeutics Inc.行情,Arcutis Biotherapeutics Inc.股票行情,Arcutis Biotherapeutics Inc.股价,Arcutis Biotherapeutics Inc.股市,Arcutis Biotherapeutics Inc.股票价格,Arcutis Biotherapeutics Inc.股票交易,Arcutis Biotherapeutics Inc.股票购买,Arcutis Biotherapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction